Effect of Liraglutide, 3.0 mg, Once Daily vs Placebo Over Time
weight loss
SECONDARY
A per-protocol analysis for those with an in-person body weight measurement (30 participants in the liraglutide, 3.0 mg, group and 23 participants in the placebo group) showed greater percentage change in body weight in the liraglutide, 3.0 mg, group compared to the placebo group (mean [SD], −9.05 [4.85] vs −0.86 [3.23], respectively) with an adjusted mean difference of −7.67 (95% CI, −10.14 to −5.21; Self-reported weights were used in addition to the original data available for a sensitivity analysis, resulting in 32 participants in the liraglutide, 3.0 mg, group and 34 in the placebo group. The mean (SD) percentage change in body weight from baseline to 24 weeks was −8.65 (4.96) in the liraglutide, 3.0 mg, and −0.14 (3.28) in the placebo group with an adjusted mean difference of −8.29 (95% CI, −10.42 to −6.16).Next, we examined the effect of liraglutide, 3.0 mg, compared to placebo on categorical weight loss (eTable 2 and eFigure 3 in Results from the anthropometric, cardiometabolic, and physical function secondary outcome analyses are presented in 